Yelena Bisharyan: Revolutionizing Therapeutics Discovery
Yelena Bisharyan, Director Of Business Development at Harvard University, shared a post by Harvard Office of Technology Development (OTD), on LinkedIn:
”Well done Christina Woo, Nandini Vallavoju and Angel Ni! Cyclimid therapeutics team at Harvard has developed a high throughput platform to quickly generate millions of cyclimid glue degraders, a novel class of ligands for cereblon with extensive synthetic scope and chemical tunability, addressing a major challenge in TPD space and at the same time enabling therapeutics discovery and development to undruggable targets.
Our initial focus is oncology, however, the platform is applicable to therapeutic areas such as CNS, neurodegeneration as well as inflammation, and autoimmune disorders. We have initial proof of concept validation of our approach with hits identified to multiple targets in oncology. Special thanks to our mentors at Atlas Venture, Vertex Ventures HC, Alexandria Ventures.”
Quoting Harvard Office of Technology Development (OTD)’s post:
”Harvard Professor Christina Woo presented at this year’s Science to Startup event, where innovators came together to inspire one another on the journey from translational research to startup formation. Christina Woo pitched her technology in cyclimid therapeutics, leveraging endogenous cereblon ligands as warheads to precisely control the degradation of unwanted proteins.
The research team is receiving funding and support from the Blavatnik Biomedical Accelerator to advance the technology towards commercialization. Congratulation on a great presentation Christina Woo.”
Source: Yelena Bisharyan/LinkedIn and Harvard Office of Technology Development (OTD)/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023